Infant Bacterial Therapeutics
Company Details
Status: Public
Employees: 1-10
Location:
Stockholm, Stockholm County, Sweden
Type:
sample
Technology:
sample
sample
About: Infant Bacterial Therapeutics AB (IBT) is a pharmaceutical company dedicated to developing drugs that prevent diseases in premature infants and combat the spread of antibiotic-resistant illnesses. IBT’s primary focus is on IBP-9414, a drug candidate containing Lactobacillus reuteri, a bacterial strain found in breast milk. The aim of IBP-9414 is to reduce the occurrence of necrotizing enterocolitis (NEC) and improve sustained feeding tolerance (SFT) in premature infants. Currently, IBP-9414 is undergoing a pivotal Phase III study for registration. IBT also has other drug candidates, including IBP-1016 for treating gastroschisis, IBP-1118 for preventing retinopathy of prematurity (ROP), and IBP-1122 for eliminating vancomycin-resistant enterococci (VRE) causing hospital acquired infections. By developing these drugs, IBT addresses medical needs that lack available treatments.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Infant Bacterial Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.